Company Overview and News

0
Gabon Oil Workers Start 15-Day Strike At Total Facilities

2018-07-09 rigzone
LIBREVILLE, July 9 (Reuters) - Gabon oil workers' union ONEP began a 15-day strike at the facilities of French oil producer Total on Monday after demands for higher pay and other issues were not met, the union said in a statement.
ELFGF EC

0
Gabon Oil Workers Threaten 15-Day Strike At Total Facilities

2018-06-26 rigzone
LIBREVILLE, June 26 (Reuters) - Gabon's oil workers' union ONEP plans to start a 15-day strike at the facilities of French oil firm Total on Sunday if its demands for higher pay and other benefits are not met, it said in a letter to Total Gabon.
ELFGF EC

0
UPDATE 1-Gabon oil workers threaten 15-day strike at Total facilities

2018-06-26 reuters
LIBREVILLE, June 26 (Reuters) - Gabon’s oil workers’ union ONEP plans to launch a 15-day strike at the facilities of French oil firm Total on Sunday if its demands are not met for higher pay and other benefits, it said in a letter to Total Gabon.
ELFGF EC

0
Gabon oil workers threaten 15-day strike at Total facilities

2018-06-26 reuters
LIBREVILLE, June 26 (Reuters) - Gabon’s oil workers’ union, ONEP, plans to launch a 15-day strike at the facilities of French oil producer Total on Sunday if its demands are not met for higher pay and other issues, it said in a letter to Total Gabon seen by Reuters on Tuesday.
ELFGF EC

0
Oil Workers at Total's Gabon Unit Threaten 15-Day Strike - Bloomberg

2018-06-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ELFGF EC

4
Vantage Drilling Company's (VTG) CEO Ihab Toma on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good morning, ladies and gentlemen and welcome to the Vantage Drilling International First Quarter 2018 Conference Call. Today's conference is being recorded.
ELFGF DB EC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EPA:EC / TOTAL GABON on message board site Silicon Investor.

StrikeForce Technologies Technology Stocks u0026 Market Talk With Don Wolanchuk
Biotech Valuation Mainstream Politics and Economics
Buy and Sell Signals, and Other Market Perspectives Shiny Objects
Underexposed Technical Analysis Reliq Health Technologies Inc
Le coin des prospecteurs Verde Agritech